Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program

Rhea-AI Summary

Allergan Aesthetics (NYSE: ABBV) launched the Faces of Natrelle® Testimonial Program on Feb 3, 2026, inviting U.S. women who had Natrelle® breast augmentation or reconstruction at age 22+ to submit photos, videos, and testimonials for possible publication.

Augmentation participants who are Allē members may receive five $100 Allē gift cards if selected and approved; reconstruction patients are encouraged to share but are not eligible for compensation. Important safety information and a Boxed Warning for breast implants are reiterated, including BIA-ALCL risk and recommended imaging timelines.

News Market Reaction – ABBV

+0.01%

24 alerts

+0.01% News Effect

-5.4% Trough in 1 hr 15 min

+$40M Valuation Impact

$398.83B Market Cap

0.1x Rel. Volume

On the day this news was published, ABBV gained 0.01%, reflecting a mild positive market reaction. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 24 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $40M to the company's valuation, bringing the market cap to $398.83B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Augmentation age minimum: 22 years Reconstruction age minimum: 18 years Testimonial reward: $500 in Allē gift cards +5 more

8 metrics

Augmentation age minimum 22 years Eligibility for Natrelle augmentation patients in testimonial program

Reconstruction age minimum 18 years FDA-approved age for saline-filled implants in augmentation context

Testimonial reward $500 in Allē gift cards Potential compensation for selected augmentation participants who are Allē members

Gift card structure Five $100 gift cards Allē gift card issuance per approved Program Eligible Participant

Content approval timeline 90 days Timeframe to send Allē gift cards after content approval

Surgeon survey size 492 surgeons Survey base for #1 implant brand claim, September 2025

MRI/ultrasound start 5–6 years Recommended first imaging interval after silicone implant surgery

Repeat imaging interval Every 2–3 years Recommended ongoing imaging frequency for silicone implant rupture monitoring

Market Reality Check

Price: $228.46 Vol: Volume 5,229,526 vs 20-da...

normal vol

$228.46 Last Close

Volume Volume 5,229,526 vs 20-day average 7,463,413 (relative volume 0.7x), indicating lighter-than-usual trading. normal

Technical Shares trade above the 200-day MA, at $225.64 vs $208.66, reflecting a pre-existing uptrend.

Peers on Argus

ABBV was up 1.18% while large-cap peers like JNJ, AZN, NVS, LLY, and NVO each sh...

1 Down

ABBV was up 1.18% while large-cap peers like JNJ, AZN, NVS, LLY, and NVO each showed modest gains between about 0.49% and 1.77%. Momentum scans only flagged PFE moving down, suggesting ABBV’s move was more stock-specific than part of a broad momentum wave.

Historical Context

5 past events · Latest: Jan 29 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 29	Migraine education campaign	Positive	+0.8%	Launch of Love in Mind™ educational initiative on migraines and relationships.
Jan 28	Aesthetics data presentation	Positive	-2.4%	New facial injectable data and symposia at IMCAS 2026 in Paris.
Jan 16	Phase 3 lymphoma data	Neutral	-1.1%	Topline epcoritamab Phase 3 DLBCL results with PFS benefit but no OS gain.
Jan 12	US pricing agreement	Neutral	+0.3%	Three-year access and affordability agreement with Trump administration.
Jan 12	Oncology licensing deal	Positive	-0.0%	Exclusive license for RC148 bispecific antibody in advanced solid tumors.

Pattern Detected

Recent news has mostly been strategic or educational initiatives with mixed but generally modest price reactions; one positive aesthetics data update saw a short-term selloff.

Recent Company History

Over the past months, ABBV headlines have spanned educational campaigns, aesthetics data, oncology trial results, pricing/access agreements, and a major oncology licensing deal. The latest news continues Allergan Aesthetics’ consumer-facing efforts, similar in tone to the Love in Mind™ initiative on Jan 29, 2026. Earlier, IMCAS 2026 aesthetics data coincided with a -2.35% move, while the RemeGen licensing deal on Jan 12, 2026 and the migraine relationship campaign saw muted price reactions, underscoring that brand and medical-education news has not driven large swings historically.

Market Pulse Summary

This announcement highlights a consumer-facing initiative for Natrelle® implants, using patient test...

Analysis

This announcement highlights a consumer-facing initiative for Natrelle® implants, using patient testimonials and limited-time Allē® gift card incentives of up to $500 for eligible augmentation participants. It reinforces Allergan Aesthetics’ focus on education and empowerment while emphasizing detailed safety information, imaging guidance every 2–3 years, and candid discussion of risks such as BIA-ALCL. Investors may track how such programs support the broader aesthetics franchise alongside clinical data and major strategic deals in AbbVie’s pipeline.

Key Terms

breast implant–associated anaplastic large cell lymphoma, autoimmune diseases, chemotherapy, radiation therapy, +4 more

8 terms

breast implant–associated anaplastic large cell lymphoma medical

"Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL)."

A rare form of immune-system cancer that can develop in the scar tissue or fluid around some breast implants, typically appearing as swelling, a lump, or pain near the implant. It matters to investors because diagnoses can prompt product recalls, regulatory scrutiny, legal claims, and changes in sales or insurance costs for implant makers and related suppliers—similar to how a defective car part can trigger recalls, lawsuits, and lost revenue.

autoimmune diseases medical

"Tell your doctor if you have any of the following conditions, as the risks of breast implant surgery may be higher:Autoimmune diseases (eg, lupus and scleroderma)…"

Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.

chemotherapy medical

"Planned chemotherapy or radiation therapy following breast implant placement"

Chemotherapy is the use of drugs to kill or slow the growth of cancer cells, typically given as pills or intravenous infusions; because these drugs target rapidly dividing cells they can also harm healthy tissue and cause side effects. It matters to investors because clinical trial results, regulatory approvals, pricing and insurance coverage directly affect a drugmaker’s sales, hospital treatment patterns and overall healthcare spending—much like a new product that can change a company’s market share.

radiation therapy medical

"Planned chemotherapy or radiation therapy following breast implant placement"

Radiation therapy uses focused high-energy rays or particles to kill or shrink abnormal cells inside the body, often delivered from outside the body or by placing tiny sources near the target. Think of it like using a magnifying glass to concentrate sunlight on a small spot to remove a weed without digging up the whole garden. Investors watch radiation therapy because its effectiveness, side effects, regulatory approvals, equipment needs and reimbursement rules directly affect healthcare companies’ revenues, clinical trial outcomes and long-term costs.

capsular contracture medical

"Key complications include… capsular contracture (severe scar tissue around the implant)."

Capsular contracture is a complication that can occur after implantation of a medical device, most commonly breast implants, where the body’s scar tissue tightens around the implant and causes firmness, pain, or visible distortion. Investors care because it drives demand for corrective surgeries, influences product safety perceptions, affects regulatory scrutiny and liability risk, and can materially impact sales and costs for device makers, surgeons and insurers.

hypertrophic scarring medical

"Other complications include… nipple complications, hypertrophic scarring, and implant palpability/visibility."

Hypertrophic scarring is a raised, thickened scar that forms at the site of a healed wound when the body produces excess collagen during repair, like a patch that becomes thicker than the original fabric. For investors, it matters because the condition drives demand for medical products, therapies and cosmetic treatments, affects regulatory and clinical trial pathways for new treatments, and can influence healthcare costs and liability risks for companies in medical, dermatology and aesthetic markets.

mri medical

"If you have symptoms of or uncertain ultrasound results for breast implant rupture, an MRI is recommended."

Magnetic resonance imaging (MRI) is a medical scan that uses magnetic fields and radio waves to create detailed pictures of the inside of the body, like a high-resolution camera for tissues and organs. Investors care because MRI drives demand for imaging machines, hospital services, diagnostics and can be central to clinical trial results and regulatory decisions—changes in MRI use or technology can affect revenue, capital spending and reimbursement in healthcare and medical device markets.

mammography medical

"Routine screening mammography for breast cancer will be more difficult, and implants may rupture during the procedure."

A mammography is an X‑ray examination of breast tissue used to detect tumors, calcifications or other changes before symptoms appear. For investors, mammography matters because changes in screening technology, regulatory approvals, insurance coverage or public health guidelines directly influence demand for imaging equipment, diagnostic services and related supplies — much like how a new smartphone design can shift sales for phone makers and component suppliers.

AI-generated analysis. Not financial advice.

• The nationwide program invites eligible Natrelle^® breast augmentation and reconstruction patients to share their personal experiences.
• Natrelle^® champions women's voices to provide support at every step of their breast aesthetics journey.

IRVINE, Calif., Feb. 3, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the launch of the Faces of Natrelle^® Testimonial Program, a nationwide initiative inviting women to share their real stories and experiences with Natrelle^® breast implants to help educate, empower, and support others considering breast surgery.

"Faces of Natrelle^® is about honoring the stories, the decisions, and the transformations of women with breast implants," said Nicole Mowad-Nassar, President, Global Allergan Aesthetics and Senior Vice President, AbbVie. "Despite being some of the most popular cosmetic and reconstructive surgeries in the U.S., breast procedures are still often misunderstood due to outdated perceptions and a lingering culture of silence around them.¹ We're proud to put a spotlight on these diverse experiences through the Testimonial Program to reflect a growing cultural shift towards transparency and empowerment."

Starting today, Natrelle^® invites women who underwent breast augmentation or breast reconstruction at age 22 or older to submit a photo or video^†, along with a written testimonial describing their experience with Natrelle^® Breast Implants for the chance to be featured on the brand's social media platforms, website, and more.

Natrelle^® recognizes that every breast aesthetics journey is unique—whether driven by personal choice through breast augmentation or medically indicated through breast reconstruction. Each path comes with its own considerations, emotions, and outcomes. By sharing these stories, real patients can offer clarity and confidence to others navigating their own journey.

Participants who underwent Natrelle^® breast augmentation, and are also Allē^® Members, may be eligible to receive $500 in Allē Gift Cards^‡ if selected and their content is approved. Terms and Conditions apply. Limited-time offer. While supplies last. Eligibility limitations. See below for details. Reconstruction patients are not eligible for compensation but are encouraged to share their stories to support and inspire others in the breast reconstruction community.

Learn more about eligibly and how to apply:

• Augmentation Patients: faces.natrelle.com/augmentation
• Reconstruction Patients: faces.natrelle.com/reconstruction 

To learn more about treatment with Natrelle^®, the #1 breast implant brand selected by plastic surgeons^1* or find a provider, please visit natrelle.com, and follow along on Instagram @natrellebreastaugmentation and @natrellebreastreconstruction.

*Based on surgeon survey data, September 2025, n=492

†NATRELLE^® TESTIMONIAL PROGRAM TERMS & CONDITIONS
By submitting your video or photos, you agree to the following Terms and Conditions. Participants are eligible for the testimonial program if they had breast implantation after the age of 22 years old, are a legal resident of one of the fifty United States, including the District of Columbia, and have undergone breast augmentation surgery with Natrelle^® Breast Implants in the United States in which two (2) Natrelle^® Breast Implants are implanted during the procedure (the "Program Eligible Participants"). Program Eligible Participants may receive five (5) $100 Allē gift cards from Natrelle^® for providing content to Natrelle^® marketing. The content must meet the following requirements: (1) Submit photos or a video of yourself and a written testimonial about your experience with Natrelle^® Breast Implants. Even if a Program Eligible Participant has met the above requirements, Natrelle^® may reject a post if it is not consistent with Natrelle^® messaging, as determined by Natrelle^® in its sole discretion. Program Eligible Participants will not receive any Allē gift cards unless and until their submitted content and testimonial are approved by Natrelle^®, in its sole discretion. If approved, Natrelle^® will send five (5) $100 Allē gift cards within ninety (90) days via email to the provided email address. The Allē gift cards are subject to limited availability, for a limited time only, and are only available while supplies last. Must be an Allē Member who resides in one of the fifty United States, including the District of Columbia, to redeem gift cards. Standard Allē Loyalty Program Terms and Conditions and Allē gift card Terms & Conditions (seen below) apply. Natrelle^® reserves the right to cancel this program for any reason, at any time, without notice.

‡ALLĒ GIFT CARD TERMS & CONDITIONS
Must be an Allē Member who resides in one of the fifty United States, including the District of Columbia, to redeem gift cards. Allē gift cards are only redeemable within the United States and are not valid for use in Puerto Rico or other US territories. The Allē gift card is void where prohibited or restricted by law. Allē gift cards do not expire and cannot be applied to past transactions, or redeemed or exchanged for cash. In some states, if the gift card is unused for a number of years, the unused value of the gift card will be turned over to such state, as required by law, through a process called escheatment. Gift cards can be combined with other applicable Allē or brand-specific gift cards, Allē points, or other brand-specific offers. Members must use the complete value of each gift card in a single transaction. If a healthcare provider determines the Allē Member is an appropriate candidate for an applicable treatment, each gift card can be redeemed for $100 off the purchase of any Redemption Eligible Product at participating Allē provider offices only. Your Allē gift card will be automatically added to your Allē Wallet and can be redeemed on any qualifying brand at a participating Allē provider. To view your gift card, all available Allē gift cards are stored in your Allē Wallet. Standard Allē Loyalty Program Terms and Conditions apply. Allergan Aesthetics, an AbbVie company, reserves the right to alter or cancel this offer at any time. If you have questions, please contact Allē Customer Support at 1-888-912-1572 Monday-Friday, 8 am–6 pm CT.

Natrelle^® Breast Implants IMPORTANT SAFETY INFORMATION AND APPROVED USES

Breast implants are not considered lifetime devices. The longer people have them, the greater the chances are that they will develop complications, some of which will require more surgery.

Breast implants have been associated with the development of a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). This cancer occurs more commonly in patients with textured breast implants than smooth implants, although rates are not well defined. Some patients have died from BIA-ALCL.

Patients receiving breast implants have reported a variety of systemic symptoms, such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established. Some patients report complete resolution of symptoms when the implants are removed without replacement.

Who can get breast implants?
Natrelle^® Breast Implants are approved for the following:

• Breast augmentation for women at least 22 years old for silicone-filled implants and for women at least 18 years old for saline-filled implants. Breast augmentation includes primary breast augmentation to increase the breast size and revision surgery to correct or improve the result of a primary breast augmentation
• Breast reconstruction. This includes primary breast reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. This also includes revision surgery to correct or improve the result of a primary breast reconstruction

Who should NOT get breast implants?
Breast implant surgery should NOT be performed in:

• Women with active infection anywhere in their body
• Women with existing cancer or precancer of their breast who have not received adequate treatment for those conditions
• Women who are currently pregnant or nursing 

What should I tell my doctor?
Tell your doctor if you have any of the following conditions, as the risks of breast implant surgery may be higher:

• Autoimmune diseases (eg, lupus and scleroderma)
• A weakened immune system (eg, taking medications to decrease the body's immune response)
• Planned chemotherapy or radiation therapy following breast implant placement
• Conditions or medications that interfere with wound healing and blood clotting
• Reduced blood supply to breast tissue
• Clinical diagnosis of depression or other mental health disorders, including body dysmorphic disorder and eating disorders
• Those with a diagnosis of depression or other mental health disorders should wait for resolution or stabilization of these conditions prior to undergoing breast implantation surgery

What else should I consider?

• There is a Boxed Warning for breast implants. Please see bold text at beginning
• Many changes to your breasts following implantation are irreversible. If you later choose to have your implants removed and not replaced, you may experience dimpling, puckering, wrinkling, or other cosmetic changes, which may be permanent
• Breast implantation is likely not a one-time surgery. The longer implants are in place, the greater the potential risk for complications. You will likely need additional surgeries on your breasts due to complications or unacceptable cosmetic results. Thus, you should also consider the complication rates for later (revision) surgery since you may experience these risks in the future
• Cancer treatments and surgery will affect the outcome and timing of breast reconstruction
• Breast implants may affect your ability to breastfeed, either by reducing or eliminating milk production
• Rupture of a silicone-filled breast implant is most often silent. Even if you have no symptoms, you should have your first ultrasound or MRI at 5 to 6 years after your initial implant surgery and then every 2 to 3 years thereafter regardless of whether your implants are for augmentation or reconstruction. If you have symptoms of or uncertain ultrasound results for breast implant rupture, an MRI is recommended. Additional imaging may be required depending on your medical history and status. The health consequences of a ruptured silicone gel-filled breast implant have not been fully established
• Routine screening mammography for breast cancer will be more difficult, and implants may rupture during the procedure. Perform self-examination every month for cancer screening and ask your surgeon to help you distinguish the implant from your breast tissue. Lumps, persistent pain, swelling, hardening, or changes in implant shape should be reported to your surgeon and possibly evaluated with imaging 

What are key complications with breast implants? 
Key complications include reoperation, implant removal with or without replacement, implant rupture with silicone-filled implants, implant deflation with saline-filled implants, and capsular contracture (severe scar tissue around the implant). Other complications include breast pain, swelling, asymmetry, wrinkling/rippling, implant malposition nipple complications, hypertrophic scarring, and implant palpability/visibility.

Talk to your doctor about other complications.

For more information, see the patient brochures at www.allergan.com/products.
To report a problem with Natrelle^® Breast Implants, please call Allergan^® at 1-800-624-4261.

The sale and distribution of Natrelle^® Breast Implants is restricted to licensed physicians who provide information to patients about the risks and benefits of breast implant surgery.

About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

References: 

1. Natrelle^® Data on file 2023 – 2024. Accessed September 9, 2024. 

© 2025 AbbVie. All rights reserved. All trademarks are the property of their respective owners.

Contacts:

Allergan Aesthetics Media:
Ember Garrett
+1 (949) 413-6091
Garrett_ember@allergan.com 

AbbVie Investors:
Liz Shea
+1 (847) 935-2211
Liz.Shea@abbvie.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/allergan-aesthetics-continues-its-mission-of-empowering-women-through-the-faces-of-natrelle-testimonial-program-302677692.html

SOURCE AbbVie

FAQ

What is the Faces of Natrelle® Testimonial Program announced by Allergan Aesthetics (ABBV) on Feb 3, 2026?

The program invites U.S. women 22+ who had Natrelle® implants to submit photos, videos, and testimonials for possible feature. According to the company, selected augmentation Allē members may receive five $100 Allē gift cards if content is approved and supply lasts.

How much compensation does Allergan Aesthetics (ABBV) offer for Natrelle® augmentation testimonials?

Selected augmentation participants who are Allē members may receive five $100 Allē gift cards (total $500). According to the company, gift cards are issued only after Natrelle® approves submitted content and are subject to availability and Allē terms.

Are Natrelle® breast reconstruction patients eligible for compensation in the Faces of Natrelle® program (ABBV)?

No, reconstruction patients are not eligible for Allē gift card compensation under this program. According to the company, reconstruction participants are encouraged to share stories to support others but will not receive payment.

What eligibility rules apply for submitting to the Natrelle® testimonial program from Allergan Aesthetics (ABBV)?

Submitters must be legal U.S. residents who had two Natrelle® implants placed at age 22 or older for augmentation. According to the company, content must meet Natrelle®'s requirements and approval is at Natrelle®'s sole discretion.

What key safety information does Allergan Aesthetics (ABBV) repeat about Natrelle® breast implants in this announcement?

Breast implants are not lifetime devices and carry risks including BIA-ALCL and potential need for additional surgery. According to the company, recommended imaging begins at 5–6 years post-implant and then every 2–3 years, as clinically indicated.